Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 231

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

The Performance of MelaFind: A Prospective Multicenter Study

Monheit, Gary, Cognetta, Armand B., Ferris, Laura, Rabinovitz, Harold, Gross, Kenneth, Martini, Mary, Grichnik, James M., Mihm, Martin, Prieto, Victor G., Googe, Paul, King, Roy, Toledano, Alicia, Kabelev, Nikolai, Wojton, Maciej, Gutkowicz-Krusin, Dina·2011·Archives of Dermatology

Abstract

OBJECTIVE: To demonstrate the safety and effectiveness of MelaFind, a noninvasive and objective computer-vision system designed to aid in detection of early pigmented cutaneous melanoma. DESIGN: A prospective, multicenter, blinded study. The diagnostic performance of MelaFind and of study clinicians was evaluated using the histologic reference standard. Standard images and patient information for a subset of 50 randomly selected lesions (25 melanomas) were used in a reader study of 39 independent dermatologists to estimate clinicians' biopsy sensitivity to melanoma. SETTING: Three academic and 4 community practices in the United States with expertise in management of pigmented skin lesions. PATIENTS: A total of 1383 patients with 1831 lesions enrolled from January 2007 to July 2008; 1632 lesions (including 127 melanomas-45% in situ-with median Breslow thickness of invasive lesions, 0.36 mm) were eligible and evaluable for the study end points. MAIN OUTCOME MEASURES: Sensitivity of MelaFind; specificities and biopsy ratios for MelaFind and the study investigators; and biopsy sensitivities of independent dermatologists in the reader study. RESULTS: The measured sensitivity of MelaFind was 98.4% (125 of 127 melanomas) with a 95% lower confidence bound at 95.6% and a biopsy ratio of 10.8:1; the average biopsy sensitivity of dermatologists was 78% in the reader study. Including borderline lesions (high-grade dysplastic nevi, atypical melanocytic proliferations, or hyperplasias), MelaFind's sensitivity was 98.3% (172 of 175), with a biopsy ratio of 7.6:1. On lesions biopsied mostly to rule out melanoma, MelaFind's average specificity (9.9%) was superior to that of clinicians (3.7%) (P=.02). CONCLUSION: MelaFind is a safe and effective tool to assist in the evaluation of pigmented skin lesions. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00434057.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/archdermatol.2010.302

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 231

Metadata

Authors
Monheit, G., Cognetta, A. B., Ferris, L., Rabinovitz, H., Gross, K., Martini, M., Grichnik, J. M., Mihm, M., Prieto, V. G., Googe, P., King, R., Toledano, A., Kabelev, N., Wojton, M., & Gutkowicz-Krusin, D.
Venue
Archives of Dermatology
Published
2011-02-01
Volume
147
Issue
2
Pages
188
ISSN
0003-987X (ISSN-L)
OpenAlex
W2128756499
Cited by
231
References
5
FWCI
4.70
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Performance of MelaFind: A Prospective Multicenter Study. https://app.cochat.ai/papers/10.1001/archdermatol.2010.302
The paper
Monheit, G., Cognetta, A. B., Ferris, L., Rabinovitz, H., Gross, K., Martini, M., Grichnik, J. M., Mihm, M., Prieto, V. G., Googe, P., King, R., Toledano, A., Kabelev, N., Wojton, M., & Gutkowicz-Krusin, D. (2011). The Performance of MelaFind: A Prospective Multicenter Study. Archives of Dermatology. https://doi.org/10.1001/archdermatol.2010.302

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.